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We aimed to evaluate the performance of the Khorana score in pre-dicting venous thromboembolic events in ambulatory cancerpatients. Embase and MEDLINE were searched from January
2008 to June 2018 for studies which evaluated the Khorana score. Two
authors independently screened studies for eligibility, extracted data, and
assessed risk of bias. Additional data on the 6-month incidence of venous
thromboembolism were sought by contacting corresponding authors. The
incidence in each Khorana score risk group was estimated with random
effects meta-analysis. A total of 45 articles and eight abstracts were includ-
ed, comprising 55 cohorts enrolling 34,555 ambulatory cancer patients. For
27,849 patients (81%), 6-month follow-up data were obtained. Overall,
19% of patients had a Khorana score of 0 points, 64% a score of 1 or 2
points, and 17% a score of 3 or more points. The incidence of venous
thromboembolism in the first six months was 5.0% (95%CI: 3.9-6.5) in
patients with a low-risk Khorana score (0 points), 6.6% (95%CI: 5.6-7.7) in
those with an intermediate-risk Khorana score (1 or 2 points), and 11.0%
(95%CI: 8.8-13.8) in those with a high-risk Khorana score (3 points or high-
er). Of the patients with venous thromboembolism in the first six months,
23.4% (95%CI: 18.4-29.4) had been classified as high risk according to the
Khorana score. In conclusion, the Khorana score can be used to select
ambulatory cancer patients at high risk of venous thromboembolism for
thromboprophylaxis; however, most events occur outside this high-risk
group.  
The Khorana score for prediction of venous
thromboembolism in cancer patients: 
a systematic review and meta-analysis
Frits I. Mulder,1,2 Matteo Candeloro,3 Pieter W. Kamphuisen,1
Marcello Di Nisio,3 Patrick M. Bossuyt,2 Noori Guman,2 Kirsten Smit,2
Harry R. Büller,2 and Nick van Es2 on behalf of the CAT-prediction
collaborators
1Tergooi Hospitals, Department of Internal Medicine, Hilversum, the Netherlands;
2Amsterdam UMC, University of Amsterdam, Department of Vascular Medicine,
Amsterdam Cardiovascular Science, Amsterdam, the Netherlands; 3University G.
D’Annunzio, Department of Medicine and Ageing Sciences, Chieti, Italy
ABSTRACT
Introduction
Venous thromboembolism (VTE) is a burdensome and frequent complication in
patients with active cancer. The estimated overall 12-month incidence is approxi-
mately 6-8% but varies widely across tumor types.1,2 VTE is associated with sub-
stantial morbidity and mortality,3 decreases quality of life,4 and can lead to interrup-
tion or discontinuation of cancer treatment. Although thromboprophylaxis effec-
tively reduces the risk of VTE,5 current guidelines recommend against its routine
use in ambulatory cancer patients, probably due to the high number that require
treatment, the fear of bleeding, and the considerable burden associated with daily
injections of low-molecular-weight heparins.6 
Risk stratification tools may help to reduce the number requiring treatment by
guiding selection of cancer patients at high risk of VTE. An ideal risk score would
help clinicians identify both patients with a negligible risk as well as those at very
high risk needing intervention. The best-known risk stratification tool is the
Khorana score, which was introduced in 2008. This score assigns points to five clin-
ical and pre-chemotherapy laboratory parameters: primary tumor site (+1 or 2
points), platelet count of 350x109/L or more (+1 point),
hemoglobin concentration of 100 g/L or lower or use of
erythropoiesis-stimulating agents (+1 point), leukocyte
count of 11x109/L or higher (+1 point), and a Body Mass
Index of 35 kg/m2 or higher (+1 point) (Table 1).7 A sum
score of 0 points classifies patients as being at low risk of
VTE, 1 or 2 points at intermediate risk, and those with 3
or more points at high risk. The Khorana score is endorsed
by the latest guideline updates of the American Society of
Clinical Oncology and the National Comprehensive
Cancer Network to select ambulatory cancer patients for
thromboprophylaxis.6,8 
Over 50 studies have evaluated the score since its publi-
cation, but reported results were often conflicting. A clear
interpretation of these findings is further hampered by the
substantial variation in study design, cancer types includ-
ed, and duration of follow up, ranging from a median of 2
to 79 months.9,10 
To obtain valid and interpretable summary estimates of
the performance of the Khorana score, based on the evi-
dence available, we performed a systematic review and
meta-analysis, specifically focusing on 6-month follow-up
outcomes of all published relevant studies by obtaining
additional data, thereby minimizing between-study het-
erogeneity. Our findings provide physicians with clinically
useful data on the absolute risks of VTE associated with a
low-, intermediate-, and high-risk Khorana score in ambu-
latory patients with cancer.
Methods
This report adheres to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidance (See
checklist in Online Supplementary Table S1).11
Search strategy and data collection
A comprehensive search was performed in Embase and MED-
LINE from January 2008 to June 2018 to identify studies that had
evaluated the Khorana score in ambulatory cancer patients. In
addition, studies presented as abstracts at conferences of the
American Society of Hematology (ASH) or the International
Society on Thrombosis and Haemostasis (ISTH) were identified
by a manual search. Two reviewers (FIM and MC) independently
screened studies and assessed bias with the Quality in Prognosis
Studies (QUIPS) tool.12 The search strategy is shown in Online
Supplementary Table S2, and a full explanation of study selection,
data extraction, and bias assessment is provided in Online
Supplementary list 1. 
Additional data 
Because the number of events are expected to increase with the
duration of follow up, we evaluated the incidence of VTE during
a pre-specified follow-up duration to minimize between-study
heterogeneity in observation time. Since the majority of venous
thromboembolic events occur in the first six months after start of
chemotherapy,1 this 6-month follow-up period was considered
most relevant. Corresponding authors of included studies not
reporting the 6-month period were contacted and invited to pro-
vide additional data for this period. 
Statistical analysis
The primary outcome measure was the proportion of cancer
patients who developed VTE during the first six months of study
follow up in those with a low (0 points), intermediate (1-2 points),
or high  (3 or more points) Khorana score. VTE was defined as the
composite of radiologically confirmed symptomatic or incidental
distal or proximal lower-extremity deep-vein thrombosis, upper-
extremity deep-vein thrombosis, or pulmonary embolism. Studies
with a fixed follow-up time less than six months in their study
design were not included in the analysis of the 6-month outcomes.
The derivation cohort of the Khorana score was excluded from
analysis.7 As currently ongoing clinical trials (clinicaltrials.gov identi-
fier: 02048865 and 02555878) select patients with a score of 2 or
more for thromboprophylaxis; the primary outcome was also
assessed for this alternative positivity threshold. Secondary out-
come measures included the proportion of patients with VTE dur-
ing overall follow up, the proportion of VTE occurring in the high-
risk group, and the relative risk of VTE for patients with a high-
risk score (≥3 points) versus those with a low-to-intermediate risk
score (0-2 points) in the first six months and during complete fol-
low up. A sensitivity analysis was performed restricted to studies
not judged to be at high risk of bias in any of the domains. 
A random effects model with logit transformation and inverse
variance weighting was used to calculate summary estimates.
Forest plots are presented with back-transformed study-specific
estimates and corresponding 95% confidence and prediction inter-
vals. Between-study heterogeneity was assessed by calculating
tau-squared (τ2) using restricted maximum likelihood estimation.
Differences between subgroups were tested for significance with
a χ2 test. P<0.05 was considered statistically significant.
Publication bias was explored with a funnel plot using the relative
risk between high- and low-to-intermediate risk patients on the x-
axis.13 Analyses were performed with R computing software, ver-
sion 3.4.3 (R Foundation for Statistical Computing, Vienna,




The database and manual search yielded 1,826 unique
articles and 53 abstracts, of which 1,641 were excluded on
the basis of title and abstract (Figure 1). Another 50 studies
were excluded after full-text assessment because the
Khorana score was not reported (n=31), VTE incidence
was not reported (n=6), the study population only com-
prised patients with VTE (n=6), the cohort was a duplicate
report (n=5), or the study had a case-control design (n=2). 
A total of 45 articles and eight abstracts were included
in the analysis, comprising 55 cohorts and 34,555 ambula-
tory cancer patients, of whom 2,386 (6.9%) were diag-
nosed with VTE during follow up. Most studies included
patients with various tumors (n=22; 42%), while others
had confined recruitment to patients with gastrointestinal
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Table 1. Khorana risk score.
Patients’ characteristics                                                        Risk score
Site of cancer                                                                                                    
Very high risk (stomach, pancreas)                                                        2
High risk (lung, lymphoma, gynecological, bladder, or testicular)  1
Prechemotherapy platelet count ≥350 x 109/L                                        1
Prechemotherapy hemoglobin level <100 g/L                                         1
or use of red cell growth factors                                                                 
Prechemotherapy leukocyte count >11 x 109/L                                       1
Body Mass Index ≥35 kg/m2                                                                        1
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Table 2. Studies with relevant characteristics.
Author (year)                           Type             Study        Newly              VTE        Cancer     Median               Study               Total               First 6 months:
                                                                  design‡    diagnosed      screening      type      follow up        population*      follow up:                 patients
                                                                                cancer only        before                     duration                                   patients             with VTE, n (%)
                                                                                                      study start                 (months)                             with VTE, n (%)                    
Abdel-Razeq (2017)25                Article      Retrospective      No                     No           Various           40                       1,677               96 (5.7%)                     83 (4.9%)
Ades (2015)26                               Article      Retrospective      No                     No        Colorectal      27.5                       151               35 (23.2%)                    15 (9.9%)
Austin (2017)27                          Abstract    Retrospective      NR                     No           Various           12                         740                72 (9.7%)                     64 (8.6%)
Ayyappan (2016)28                     Abstract    Retrospective     Yes                    No           DLBCL           46                         241               45 (18.7%)                   29 (12.0%)
Bezan-Graz (2017)10                   Article      Retrospective      NR                     No         Testicular       79.2                       586                30 (5.1%)                     27 (4.6%)
Bezan-Zurich (2017)10               Article      Retrospective      NR                     No         Testicular        NR                        303                21 (6.9%)                     21 (6.9%)
Borchmann (2016)29                 Abstract    Retrospective      No                     No               HL               12                       5,409              169 (3.1%)                   158 (2.9%)
Cella (2017)30                              Article        Prospective        NR                    Yes          Various          8.3                         827                52 (6.3%)                     38 (4.6%)
Ferroni (2015)31                          Article        Prospective        Yes                    No           Various          9.2                         810                54 (6.7%)                     43 (5.3%)
Ferroni (2012)32                          Article      Retrospective     Yes                    No             Lung             6.9                         108               16 (14.8%)                   14 (13.0%)
Fuentes (2017)33                        Article      Retrospective     Yes                    No           Gastric         21.3                       108                 9 (8.3%)                       4 (3.7%)
George (2011)34,35                      Article        Prospective        NR                     NR           Various            6                         1,553               53 (3.4%)                     53 (3.4%)
Guadagni (2017)36                      Article      Retrospective     Yes                    No   Gastrointestinal 11.0                       342                32 (9.4%)                     24 (7.0%)
Kearney (2009)37                       Abstract    Retrospective      NR                     No           Various          NR                        112               23 (20.5%)                          NR
Khorana (2017)38                        Article        Prospective        No                    Yes          Various          2.8                          48                10 (20.8%)                   10 (20.8%)
Khorana (2014)39                        Article        Prospective        Yes                    Yes          Various          3.7                          35                 8 (22.9%)                     8 (22.9%)
Khorana-cohort 2 (2008)7         Article        Prospective        No                     No           Various          2.4                       1,365               28 (2.1%)                           NR
Kim (2012)40                                Article      Retrospective     Yes                    No           Various         18.9                         90                15 (16.7%)                          NR
Kruger (2017)41                           Article      Retrospective      No                     No        Pancreatic       9.2                         111               16 (14.4%)                    11 (9.9%)
Kuderer (2017)42                        Article        Prospective        NR                     No             Lung             6.0                       1,780              111 (6.2%)                   111 (6.2%)
Kuk (2017)43                                 Article      Retrospective     Yes                    No           Ovarian          NR                         57                  5 (8.8%)                            NR
Kunapareddy (2017)44              Abstract       Prospective        NR                     No           Various          7.9                         191               25 (13.1%)                   25 (13.1%)
Lim (2015)45                                 Article      Retrospective     Yes                    No           DLBCL          41.9                       322                29 (9.0%)                     25 (7.8%)
Lubberts (2016)46                       Article        Prospective        Yes                    No         Testicular       33.0                         72                  4 (5.6%)                       3 (4.2%)
Lustig (2015)47                            Article        Prospective        No                     No           Various          3.0                         580                35 (6.0%)                     35 (6.0%)
Mandala (2012)9                          Article        Prospective        No                     No           Various          2.0                       1,412               56 (4.0%)                           NR
Mansfield (2016)48                     Article      Retrospective      NR                     No             Lung           15.2                       658               79 (12.0%)                    44 (6.7%)
Misch (2013)49                             Article      Retrospective      No                     No           Glioma          NR                         38                 4 (10.5%)                           NR
Moore (2011)50                           Article      Retrospective      NR                     No           Various          NR                        932              168 (18.0%)                         NR
Munoz-Martin (2018)51              Article        Prospective        NR                     No           Various          6.0                         389               71 (18.3%)                   71 (18.3%)
Munoz-Martin (2014)52              Article      Retrospective      No                     No        Pancreatic       9.5                          73                22 (30.1%)                   14 (19.2%)
Noble (2015)53,54                        Article        Prospective        Yes                    NR             Lung             6,0                       1,068               69 (6.5%)                     69 (6.5%)
Panizo (2015)55                            Article        Prospective        No                     No           Various          3.0                         841                43 (5.1%)                     43 (5.1%)
Papaxoinis56                                 Article      Retrospective     Yes                    No   Gastrointestinal 43.0                       526                49 (9.3%)                     49 (9.3%)
Park (2017)57                                Article        Prospective        Yes                    No           Gastric         10.8                       241                23 (9.5%)                     14 (5.8%)
Patel (2015)58                              Article        Prospective        Yes                    No          Prostate        24.0                       948                58 (6.1%)                     41 (4.3%)
Pelzer (2013)24,59                        Article        Prospective        Yes                    No        Pancreatic      12.0                       144               21 (14.6%)                   21 (14.6%)
Petitto (2017)60                          Abstract       Prospective        Yes                    No           Various          6.0                         553                28 (5.1%)                           NR
Posch (2016)61                             Article        Prospective        No                     No           Various         24.0                      1,594              127 (8.0%)                    91 (5.7%)
Ramos (2016)62                           Article      Retrospective     Yes                    No        Urothelial        8.6                         943                89 (9.4%)                     55 (5.8%)
Ruch (2012)63                             Abstract    Retrospective      NR                     No        Pancreatic       8.8                          85                19 (22.4%)                          NR
Rupa-Matysek (2018)64              Article      Retrospective     Yes                    No           DLBCL          37.0                       428               64 (15.0%)                    35 (8.2%)
Rupa-Matysek (2018)65              Article      Retrospective     Yes                    No             Lung           14.0                       118              20 ((16.9%)                         NR
Santi (2017)66                              Article        Prospective        Yes                    No              NHL             6.0                       1,189               15 (1.3%)                     15 (1.3%)
Sohal (2016)67                            Abstract       Prospective        NR                     No        Colorectal       6.0                       1,593               86 (5.4%)                     86 (5.4%)
Srikanthan cohort 1 (2015)68   Article      Retrospective     Yes                    No         Testicular        NR                        207                20 (9.7%)                     20 (9.7%)
Srikanthan cohort 2 (2015)68    Article      Retrospective     Yes                    No         Testicular        NR                        105                10 (9.5%)                     10 (9.5%)
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(n=12; 23%), lung (n=6; 11%), urogenital (n=6; 11%),
hematologic (n=5; 9%), or central nervous system cancer
(n=2;  4%). Almost half of the studies had a prospective
design (n=25; 47%); the majority also included incidental-
ly detected VTE as outcome event (n=32; 60%). Study
group size ranged from 35 to 5,409 patients. Median fol-
low-up duration ranged from 2 to 79 months. Key study
characteristics of included studies are shown in Table 2. 
The 6-month follow-up data were reported in eight of
the included studies. For 11 studies, no additional data
were obtained after contacting the corresponding author
because the authors did not reply despite reminders (n=8),
were not able to retrieve the data (n=1), or where not will-
ing to share the data (n=2). For 34 studies, additional data
were obtained, yielding available 6-month data for 27,849
of the available 34,555 patients (81%). 
Risk of bias
Using the pre-specified Quality in Prognosis Studies
(QUIPS) criteria, 25 studies were judged to be at high risk
of bias for one or more of the bias domains. All eight
included abstracts and four articles were judged to be at
high risk of bias because of insufficient reporting on meth-
ods. Other reasons were a high risk of bias in the applica-
bility of the Khorana score (n=1), patient selection (n=4),
outcome (n=3), study attrition (n=2), participation (n=4),
prognostic factor measurement (n=3), outcome measure-
ment (n=5), and confounding factors (n=4). Online
Supplementary Table S4 summarizes the risk of bias assess-
ment for all studies. A funnel plot did not indicate evi-
dence of publication bias (Online Supplementary Figure S1). 
Risk classification by the Khorana score 
Overall, 6,319 patients (19%) had a Khorana score of 0
points (low risk), 21,172 patients (64%) a score of 1 or 2
points (intermediate risk), and 5,614 patients (17%) a
score of 3 or more points (high risk). The group with a
Khorana score of 0 or 1 point comprised 15,107 patients
(53%), and the group with a score of 2 points or higher
13,148 (47%). 
Incidence of venous thromboembolism in the Khorana
score risk groups
The incidence of VTE in the first 6-month period was
5.0% (95%CI: 3.9-6.5) in patients with a low-risk Khorana
score (0 points), 6.6% (95%CI: 5.6-7.7) in those with an
intermediate-risk Khorana score (1 or 2 points), and 11.0%
(95%CI: 8.8-13.8) in those with a high-risk Khorana score
(3 points or higher) (Table 3 and Figure 2A-C). The relative
risk of VTE in the first six months was 1.8 (95%CI: 1.5-
2.1) for patients with a score of 3 or higher compared to
those with a score of 2 or lower (Online Supplementary
Figure S2).  
In the high-risk Khorana score group, the reported 6-
month risk of VTE was lower in studies including patients
with lung cancer (6.4%; 95%CI: 4.9-8.4) or hematologic
malignancies (7.1%; 95%CI: 2.6-18.4) compared to stud-
ies with gastrointestinal (13.0%; 95%CI: 8.5-19.6), uro-
genital cancer (18.2%; 95%CI: 8.6-34.6), or various can-
cers (11.5%; 95%CI: 8.6-15.3, lung vs. various, P=0.0008;
hematologic vs. various, P=0.000).  The 6-month incidence
in the group with a Khorana score of 1 point or lower was
5.5% (95%CI: 4.5-6.9) compared to 8.9% (95%CI: 7.3-
10.8) in the group with a score of 2 or more points, corre-
sponding to a relative risk of 1.5 (95%CI: 1.3-1.8). 
During the overall study follow-up period, that ranged
from a median of two to 79 months, the summary inci-
dence of VTE was 5.7% (95%CI: 4.2-7.9) in patients with
a low-risk Khorana score (0 points), 8.6% (95%CI: 7.3-
10.2) in those with an intermediate-risk Khorana score (1
or 2 points), and 14.0% (95%CI:11.7-16.7) in those with a
high-risk Khorana score (3 points or higher) (Table 3 and
Online Supplementary Figure S3A-C).
Distribution of venous thromboembolic events over the
Khorana score risk groups 
Of all patients who developed VTE in the first six
months, 23.4% (95%CI: 18.4-29.4) had been classified as
high risk with the Khorana score (3 points or higher). All
other thromboembolic events occurred in the intermedi-
ate- or low-risk groups (76.6%; 95%CI:70.6 -81.6). For the
total follow-up duration, the proportion of events occur-
ring in the high-risk group was 23.7% (95%CI: 18.7-29.5). 
Sensitivity analyses 
Results were consistent in the sensitivity analysis in
which studies judged to be at high risk of bias in one or
more of the bias domains were excluded (Table 3). When
excluding these studies, the 6-month risks of VTE in
patients with a Khorana score of 0, 1 to 2, and 3 points or
higher were 4.6% (95%CI: 3.2-6.5), 6.1% ((95%CI: 5.0-
7.4), and 11.1% (95%CI: 8.3-14.7), respectively. The inci-
F.I. Mulder et al.
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Author (year)                           Type             Study        Newly              VTE        Cancer     Median               Study               Total               First 6 months:
                                                                  design‡    diagnosed      screening      type      follow up        population*      follow up:                 Patients
                                                                                cancer only        before                     duration                                   patients             with VTE, n (%)
                                                                                                      study start                in months                            with VTE, n (%)                    
Tafur (2015)69                              Article        Prospective        Yes                    No           Various         10.4                       241               29 (12.0%)                   24 (10.0%)
van Es (2017)70                            Article        Prospective        No                     No           Various          6.0                         843                53 (6.3%)                     53 (6.3%)
van Es (2017)71                            Article      Retrospective     Yes                    No        Pancreatic       7.7                         147               20 (13.6%)                    13 (8.8%)
Vathiotis72                                     Article      Retrospective     Yes                    No             Lung             3.7                         130               13 (10.0%)                     7 (5.4%)
Verso (2012)23                             Article        Prospective        No                     No           Various          3.7                         381                15 (3.9%)                     15 (3.9%)
Wang (2017)73                              Article      Retrospective      NR                     No    Hepatocellular  11.9                       270                16 (5.9%)                     11 (4.1%)
Yust-Katz (2015)74                      Article      Retrospective     Yes                    No     Glioblastoma    NR                        440               64 (14.5%)                          NR
Zahir (2017)75                              Article      Retrospective      No                     No           Various          NR                        400               42 (10.5%)                   42 (10.5%)
VTE: venous thromboembolism; n: number; DLBCL: diffuse large B-cell lymphoma; NR:not reported; NHL: non-Hodgkin lymphoma.
continued from previous page
dence in the group with a score of 2 points or higher was
8.3% (95%CI: 6.4-10.7). The relative risk of patients with
a score of 3 or higher compared to those with a lower
score was 1.9 (95%CI: 1.5-2.3). 
Discussion
This systematic review and meta-analysis examined the
performance of the Khorana score in predicting VTE in
over 34,000 patient ambulatory patients with various
types of cancer. To minimize between-study heterogene-
ity and obtain clinically relevant estimates, the main
analysis was restricted to the first six months of follow up.
During this period, the summary estimate of the risk of
VTE in patients with a high-risk Khorana score was
11.0%, which was significantly higher than in those with
a low-risk (5.0%) or intermediate-risk (6.6%) score. These
findings indicate that the Khorana score may help clini-
cians in selecting patients at high risk of VTE for thrombo-
prophylaxis, which is in support of the suggestions pre-
sented in current guidelines.
The analyses also highlight several limitations of the
score. Within the high-risk group, the estimated risk of
VTE was considerably lower for patients with lung cancer
and hematologic malignancies than for those with other
cancer types (Figure 2C). Hence, the Khorana score appears
to be less informative for these two large groups of
patients. Furthermore, the VTE incidence in patients with
a low-to-intermediate risk score was 5-7%, which indi-
cates that the residual risk in this group is still substantial.
Therefore, the Khorana score is of limited use in ruling out
a future venous thromboembolic event. Lastly, the
Khorana score is designed to select patients in the high-risk
group for thromboprophylaxis. However, about one in
four (23.4%, 95%CI: 18.4-29.4) of the venous thromboem-
bolic events occur in patients with a high-risk Khorana
score. This means that a substantial amount of cancer
patients with subsequent venous thromboembolic events
will not be identified with this form of risk stratification,
and will, therefore, not benefit from thromboprophylaxis. 
A major strength of this study is the additional data
obtained from 34 studies on the 6-month incidence of
VTE after starting chemotherapy, representing 81% of
cancer patients in the available relevant literature. This
approach minimized between-study heterogeneity related
to the broad range of reported median follow-up dura-
tions. We considered this 6-month period to be clinically
Predicting cancer-associated venous thromboembolism 
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Figure 1. PRISMA flow chart. ASH: American Society of
Hematology; ISTH: International Society on Thrombosis
and Haemostasis.
F.I. Mulder et al.
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Figure 2. Venous thromboembolism incidence in the low-, intermediate-, and high-risk group over six months. Venous thromboembolism incidence in the low-risk
(A), intermediate-risk  (B), and high-risk  (C) groups according to the Khorana score, over six months follow up.
C
most relevant. Prediction of VTE only for the first few
months of chemotherapy may be too short, since the risk
remains elevated throughout the first six months. On the
other hand, the Khorana score calculated with pre-
chemotherapy laboratory data likely predicts less well for
longer term (>6 months) than for shorter term intervals.
The inclusion of more than 50 studies enabled the meta-
analysis for various subgroups of cancer patients, showing
that the performance of the Khorana score varies across
tumor types.  A potential limitation is the substantial pro-
portion of studies judged to be at high risk of bias (Online
Supplementary Table S4). However, the sensitivity analyses
restricted to studies at low risk of bias did not materially
alter the results (Table 3). When the analysis was restricted
to studies with a prospective design or to studies without
systematic VTE screening preceding study, results were
comparable (data not shown). Additional data for the first
six months could not be obtained for eleven studies, pos-
sibly introducing sampling bias. We believe, however, that
the magnitude of this risk of bias is at best modest since 6-
month data were available in the final analyses for 81% of
all patients. Some studies included more types of venous
thromboembolic events than specified in our primary out-
come. However, these types of venous thromboembolic
events occur infrequently. A large proportion of the stud-
ies (n=32, 60%) included incidentally detected VTE,
unlike the outcome in the derivation study of the Khorana
score.7 However, we believe these events should also be
considered since clinical outcomes in patients with inci-
dental VTE are similar to those with symptomatic
events.14-16 Consequently, international guidelines regard
incidental VTE events as clinically relevant and recom-
mend anticoagulant treatment, as for patients with symp-
tomatic VTE.6,17 Despite minimizing bias due to differ-
ences in follow up by using 6-month outcome data, con-
siderable residual heterogeneity was observed in the
analyses. This is expected in meta-analyses of predictive
model performance, especially when evaluating  risk
assessment tools across various cancers.18 Nonetheless, we
believe the presented estimates overall and for subgroups
by cancer type are the most reliable ones based on the cur-
rent literature, and can help clinicians to decide whether to
use the score in their practice.
Two currently ongoing randomized trials use the
Khorana score to select cancer patients at high risk of VTE
for thromboprophylaxis (clinicaltrials.gov identifier:
02048865 and 02555878). Interestingly, these studies apply
a positivity threshold of 2 points rather than the conven-
tional 3 points. Our analyses demonstrate that this
approach increases the proportion of patients classified as
high risk (17-47%) while in parallel decreasing the
absolute risk of VTE in this group (11-9%). As a conse-
F.I. Mulder et al.





Table 3. Summary estimates for 6-month and total follow-up duration.‡
                                                                                                           Incidence                                               Relative risk versus lower    Proportion
                                                                                                              of VTE                                                                  risk groups               of all VTE
                                                           Khorana          Khorana            Khorana         Khorana         Khorana         Khorana        Khorana         Khorana
                                                            score 0          score 1-2          score ≥3        score ≤1        score≥2        score ≥3      score ≥2        score ≥3
                                                         % (95% CI)       % (95% CI)        % (95% CI)     % (95% CI)     % (95% CI)       (95% CI)       (95% CI)      % (95% CI)
6 months follow-up duration                 5.0 (3.9-6.5)       6.6 (5.6-7.7)      11.0 (8.8-13.8)   5.5 (4.5-6.9)    8.9 (7.3-10.8)    1.8 (1.5-2.1)   1.5 (1.3-1.8)  23.4 (18.4-29.4)
Total study follow-up duration*            5.7 (4.2-7.9)      8.6 (7.3-10.2)    14.0 (11.7-16.7)  6.8 (5.2-8.9)   11.3 (9.4-13.4)   1.7 (1.5-2.0)   1.5 (1.3-1.8)  23.7 (18.7-29.5)
Low and moderate bias studies only                       
6 months follow-up duration               4.6 (3.2-6.5)       6.1 (5.0-7.4)      11.1 (8.3-14.7)   5.0 (4.0-6.3)    8.3 (6.4-10.7)    1.9 (1.5-2.3)   1.6 (1.3-2.0)   24.4 (17.8-32.5
Total study follow-up duration*          4.5 (3.0-6.7)       7.6 (6.0-9.5)     13.5 (10.7-16.8)  6.3 (4.9-8.1)   10.6 (8.4-13.2)   1.8 (1.4-2.2)   1.5 (1.2-1.9)  22.9 (17.2-29.9)
‡Estimates were derived from random effects meta-analysis. *Total follow-up duration varied substantially complicating interpretation of the results at total follow-up duration.
CI: confidence interval; VTE: venous thromboembolism. 
Figure 3. Estimated incidence
of venous thrombosis and pro-
portion in the high-risk group
over six months. Estimated inci-
dence of venous thrombosis (A
and C) and proportion of venous
thromboembolic events allocat-
ed to the high-risk group (B and
D). When considering two points
or more as high-risk (C and D)
instead of three points or more
(traditional threshold, A and B),
the proportion of venous throm-
boembolic events allocated to
the high risk groups increases,
but also results in a lower inci-
dence. VTE: venous throm-
boembolism. 
Predicting cancer-associated venous thromboembolism 
haematologica | 2019; 104(6) 1285
quence, the proportion of thromboembolic events that
occur in the high-risk group increases from 23% to 55%
(Figure 3). It is a matter of debate whether the 9% risk of
VTE during the first six months is considered high enough
to justify thromboprophylaxis.
The primary aim of risk stratification with the Khorana
score is to select cancer patients with a high risk of VTE
suitable for long-term thromboprophylaxis. A meta-analy-
sis of randomized trials that compared low-molecular-
weight heparins in prophylactic doses in cancer patients
with placebo showed an absolute risk reduction of
approximately 50% during a median follow-up of ten
months (RR 0.54; 95%CI: 0.38-0.75), with an increase in
major bleeding events (RR 1.44; 95%CI: 0.98-2.11).19 As
the estimated 6-month incidence of VTE in cancer patients
with a high Khorana score is 11.0%, thromboprophylaxis
with low-molecular-weight heparins for cancer patients in
this group could result in a number requiring treatment of
approximately 19 when extrapolating the relative risk
reduction of 0.54. When considering patients with 2
points or more as high-risk, thromboprophylaxis with
low-molecular-weight heparins could result in a number
requiring treatment of 24. Recent trials showed an accept-
able safety profile of therapeutic doses of direct oral anti-
coagulants in cancer patients compared to low-molecular-
weight heparins.20,21 Since their oral administration makes
these drugs more convenient, long-term thromboprophy-
laxis would be less burdensome and, therefore, more like-
ly to be accepted by clinicians and patients. Whether the
safety and efficacy of prophylactic doses of direct oral
anticoagulants are comparable to that of low-molecular-
weight heparin in cancer patients needs to be established. 
The present meta-analysis shows that the Khorana
score can select high-risk patients for thromboprophylaxis
overall. These findings indicate that the Khorana score
may help clinicians in selecting patients at high risk of
VTE for thromboprophylaxis, which is in support of the
suggestions presented in some guidelines and could accel-
erate their implementation in clinical practice. However,
several limitations of the Khorana need to be taken into
account, including the different in predicted performance
across cancer types and the modest proportion of patients
with VTE assigned to the high-risk group. Several other
VTE prediction tools for cancer patients have been intro-
duced, which may have a better performance than the
Khorana score;22-24 these scores, however, require prospec-
tive validation. Development of risk prediction models for
bleeding events in patients with prophylactic anticoagu-
lants could help to carefully weigh the benefit risk trade-
off for thromboprophylaxis in cancer patients. In addition,
future prediction tools should aim to address the limita-
tions of the Khorana score, as outlined by this analysis.
Novel biomarkers or genetic information from tumor
biopsies could improve prediction of VTE and, therefore,
merit investigation.
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